WeQual: Eight Exceptional Women Executives Honoured in EMEA Diversity Awards
15.12.2020 18:17:00 EET | Business Wire | Press release
Eight businesswomen holding prominent executive roles in leading companies in Europe, the Middle East and Africa have been named as winners in the annual WeQual Awards (www.wequal.com/awards).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005796/en/
WeQual EMEA 2020 - Winners (Photo: Business Wire)
WeQual identifies and recognises world-class women executives, one level below the group C-suite, and is designed to promote diversity and gender equality within the group executive committees of EMEA’s largest companies.
The eight winners were selected from a shortlist of 24 finalists. The successful award holders are employed in Aryzta, Bayer’s Consumer Health Division, Bureau Veritas, Fresenius Medical Care, Ooredoo Qatar, Sodexo, Standard Chartered Bank and Unilever.
Katie Litchfield, Founder and CEO of WeQual, says: “WeQual identifies already successful senior women who are qualified to be appointed to the group C-suite. Our mission is to tackle the slow progress in appointing diverse women to executive roles and highlight successes where they occur.
“The glass-ceiling concept has been an issue for decades, and the drop-off is steepest just below the group C-suite, so it is important to champion gender equality at the top.”
The awards come at an important time for women in business. The global Covid-19 pandemic is in danger of pushing back opportunities for women to be appointed to the most senior positions. “The fact that we are able to celebrate the achievements of these women in major companies at this time sets a shining example to others,” says Katie Litchfield.
The winners are:
− Bola Adesola: Senior Vice-Chairman, Africa, Standard Chartered Bank, Nigeria. Head of Region Category.
− Dr Cora Koppe-Stahrenberg: Executive Vice President, Global Head of Human Resources, Fresenius Medical Care, Germany. People Excellence Category.
− Munera AL-Dosari: Chief Strategy Officer, Ooredoo Qatar. Strategy Development Category.
− Patricia Amaro: Digital Hub and E-commerce Director, Unilever, Spain. Digital Impact Category.
− Patricia Corsi: Global Chief Marketing and Digital Officer, Bayer’s Consumer Health Division, Switzerland. Brand Innovation Category.
− Nathalie Pousin: Chief Financial Officer, France, Africa, GSIT, Bureau Veritas, France. Finance Category.
− Petra Melander: EMEA Account Director, Sodexo, Finland. Commercial Performance Category.
− Rebeca Navarro: Chief Transformation Officer for Europe and Head of Procurement, Aryzta, Switzerland. Transformational Leadership Category.
The 24 finalists were assessed against seven criteria: Leadership, Cognitive Ability, Integrity, Drive and Resilience, Equality, Knowledge of the Business, and Personal Development. All candidates were assessed blind with no name or company revealed in their application.
To choose the winners, eight executive interviewers held 30-minute interviews with the three finalists in each category before each choosing a category winner. The judges were:
− Sir Ian Cheshire, Chairman, Barclays UK
− Viswas Raghavan, CEO EMEA, J.P. Morgan
− Warren East, CEO, Rolls-Royce
− Dame Inga Beale, Chairperson, Mediclinic
− Chris O'Shea, CEO, Centrica
− Ron Kalifa OBE, Chairman, Network International
− Tamara Box, Managing Partner EME, Reed Smith LLP
− Tulsi Naidu, CEO, Zurich Insurance Company UK
All the 24 award finalists have been given access to a range of WeQual support services and networks designed to help them make the step up to the group executive level. A quarter of WeQual award winners in the UK and USA have since been promoted to the global executive committees of FTSE and Fortune 500 companies. There are now 96 senior women involved with WeQual globally.
(Ends)
Notes to editors
About WeQual
WeQual's mission is to make businesses more inclusive by identifying exceptional women executives and address the gender imbalance across the world's Group Executive Committees. Katie Litchfield, founder and CEO of WeQual Awards, devised the new platform which calls for women senior executives to build their case as to why they deserve to be appointed to the Group Executive Committee.
- LinkedIn: https://www.linkedin.com/company/wequal-awards
- Twitter: https://twitter.com/WeQualGlobal
- YouTube: https://www.youtube.com/channel/UCBpixTLeUsQVjwrivAP9-KA
- Facebook: https://www.facebook.com/WeQualAwards
- Instagram: https://www.instagram.com/wequalglobal
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005796/en/
Contact information
Katie Litchfield
katie@wequal.com
Mobile: + 44 7796 147466
UK office: +44 20 3290 3389
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom